Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 7;78(6):1698–1710. doi: 10.1097/HEP.0000000000000502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Patient selection for the combined ALGS study population. ITCH: NCT02057692; IMAGINE-II: NCT02117713; IMAGO: NCT01903460; IMAGINE: NCT02047318; and ICONIC: NCT02160782. ^aMaralixibat dose: up to 266 µg/kg/d. ^bThere was 1 common site for the IMAGO/IMAGINE and ICONIC trials; the total number of different sites for the overall study population (N = 76) was 21. ^cMaralixibat dose: 380 µg/kg/d. ^dTwo participants had events before week 48 and also did not have week 48 laboratory samples. Abbreviation: ALGS, Alagille syndrome.